XORTX Patent Allowed For Xrx-101 Program By Japan Patent Office
| Allen Davidoff, Co-CEO | Mika Grasso, Co-CEO | |
| ... | ... | |
| +1 403 455 7727 | +1 949 244 6011 | |
Forward-Looking Statements
This press release contains“forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, as well as“forward-looking information” within the meaning of applicable Canadian securities laws. Forward-looking statements may be identified by the use of words such as“anticipate,”“believe,”“expect,”“estimate,”“plan,”“intend,”“will,”“may,”“potential,”“looks forward,” and similar expressions, and include all statements that are not statements of historical fact. These forward-looking statements include, but are not limited to, statements regarding the payment of the registration fee for, and the registration and issuance of, the Japanese Patent; the anticipated term, expiry date and scope of the Japanese Patent, including the availability of any patent term extension; the protection the Japanese Patent may provide for the XRx-101 program and the Company's other product candidates; the size, composition and strength of the Company's patent portfolio and its plans to continue to build that portfolio; the Company's evaluation of, and the potential for, partnering or licensing arrangements for the XRx-101 program and its other programs; the potential for xanthine oxidase inhibition to attenuate increases in uric acid and acute kidney injury associated with respiratory viral infection; and the advancement of the Company's XRx-101 and XRx-026 programs, its other development programs, and its strategy.
Forward-looking statements are based on the Company's current expectations and assumptions and are subject to known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among others: the risk that the registration fee is not paid or that the Japanese Patent is otherwise not registered and issued as anticipated, or at all; the risk that the Japanese Patent, once issued, is challenged, narrowed, invalidated or held unenforceable, including in post-grant opposition or invalidation proceedings before the JPO; the risk that the claims of the Japanese Patent do not cover competing products or provide meaningful commercial protection; the risk that no patent term extension is available for the Japanese Patent; the risk that the Company's pending patent applications do not issue as patents, or issue with claims narrower than those sought; the Company's ability to obtain, maintain, defend and enforce its intellectual property rights in Japan and other jurisdictions, including its ability to fund annuity and maintenance fees; the Company's need for, and ability to obtain, additional capital to fund its development programs and operations; the risk that the XRx-101 program, which is not the Company's lead program, is not further developed, partnered or approved in Japan or any other jurisdiction; the risk that the Company does not enter into any partnering or licensing arrangement on acceptable terms, or at all; the risk that xanthine oxidase inhibition does not prove to be safe or effective in treating or preventing acute kidney injury or other acute organ injury associated with viral infection; the Company's ability to advance, and obtain regulatory approval for, the XRx-026 program and its other product candidates on the timelines currently anticipated, or at all; the evolving regulatory environment applicable to the Company's business in the United States, Canada and Japan; the Company's ability to maintain the listing of its common shares on the Nasdaq Capital Market; and the Company's ability to attract and retain qualified personnel.
For a more detailed discussion of these and other risks and uncertainties, investors should review the disclosures contained under the heading“Risk Factors” in the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2025, and in the Company's subsequent Reports of Foreign Private Issuer on Form 6-K, each as filed with or furnished to the U.S. Securities and Exchange Commission (the“ SEC”) and available at , as well as in the Company's continuous disclosure documents filed with the Canadian securities regulatory authorities and available at .
The forward-looking statements in this press release speak only as of the date hereof. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned not to place undue reliance on these forward-looking statements.

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.

Comments
No comment